Team reports on synergistic cytotoxicity of HDAC and PARP inhibitors and decitabine in pancreatic cancer cells

Effects of drugs on the levels of various proteins involved in DNA repair/DNA damage response. Credit: Oncotarget (2024). DOI: 10.18632/oncotarget.28588 A new research paper titled “Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy” has been published in Oncotarget. Histone deacetylase inhibitors (HDACi) can modulate the acetylation status of proteins, influencing the genomic instability exhibited by cancer cells. Poly (ADP ribose) polymerase (PARP) inhibitors (PARPi) have a direct effect on protein poly (ADP-ribosyl)ation, which is important for DNA repair. Read More

Related posts:

  1. New discovery suggests opportunity to improve effectiveness of KRAS inhibitors against pancreatic cancer
  2. Clarifying a synergistic effect between different types of antibodies in cancer treatment
  3. How guardian proteins change from inhibitors to promoters of cancer
  4. Team finds exportin 1 governs immunosuppressive functions of myeloid-derived suppressor cells in tumors
  5. Research reports improvements in survival rates in patients with metastatic prostate cancer
  6. Reversing chemotherapy resistance in pancreatic cancer
  7. Target discovered for the treatment of pancreatic cancer
  8. Team finds new potential causes of rare and lethal bone cancer

Leave a Reply

Your email address will not be published. Required fields are marked *